Back to top
more

SiBone (SIBN)

(Delayed Data from NSDQ)

$15.40 USD

15.40
235,383

-0.12 (-0.77%)

Updated Oct 22, 2025 04:00 PM ET

After-Market: $15.41 +0.01 (0.06%) 7:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (92 out of 243)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Hologic (HOLX) Gains From New Launches as Macro Concerns Rise

by Zacks Equity Research

Hologic (HOLX) has been making impressive progress in its Breast Health arm, leveraging its strategic expansion efforts to diversify business across the patient continuum of care.

Zacks Equity Research

Abbott (ABT) Broadens Electrophysiology Footprint With TactiFlex

by Zacks Equity Research

The successful deployment of Abbott's (ABT) TactiFlex Ablation Catheter, Sensor Enabled in Canada broadens the company's global footprint in the electrophysiology space.

Zacks Equity Research

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX), backed by collaborations with health plans and upbeat guidance.

Zacks Equity Research

Abbott (ABT) Unveils Connected Diabetes App With New Pact

by Zacks Equity Research

Abbott's (ABT) FreeStyle Libre portfolio is the world's top sensor-based CGM system, changing the lives of over 5 million people.

Zacks Equity Research

Bruker (BRKR) Advances Novel 4D-Proteomics Capabilities

by Zacks Equity Research

Bruker's (BRKR) commitment to innovation and customer support makes it a great partner and helps achieve its mission of translating nature into medicine.

Zacks Equity Research

Here's Why You Should Hold on to IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

Investors are optimistic about IDEXX (IDXX) on solid premium instrument placements and upbeat guidance.

Zacks Equity Research

Phibro (PAHC) Sales Impacted by Macro Concerns, FX Headwind

by Zacks Equity Research

The COVID-19 pandemic has adversely affected the international economic conditions and financial markets, leading to an economic downturn in many countries, in which Phibro (PAHC) operates.

Zacks Equity Research

Myriad Genetics' (MYGN) New Deal to Use MRD Testing Platform

by Zacks Equity Research

Myriad Genetics (MYGN) announces a collaboration with Memorial Sloan Kettering Cancer Center to study the use of MRD testing in breast cancer.

Zacks Equity Research

Here's Why You Should Retain National Vision (EYE) Stock Now

by Zacks Equity Research

Investors are optimistic about National Vision's (EYE) stock, banking on comparable store sales growth and stable liquidity.

Zacks Equity Research

Teleflex (TFX) Rides on Urolift Prospects Amid Cost Pressures

by Zacks Equity Research

With respect to Teleflex's (TFX) market development objectives for UroLift, the company witnesses growth for UroLift in the hospital setting.

Zacks Equity Research

Teleflex (TFX) Picked for Vizient Innovative Technology Exchange

by Zacks Equity Research

Teleflex (TFX) gets selected to exhibit Arrow VPS Rhythm DLX Device and Arrow PICCs preloaded with the NaviCurve Stylet at the Vizient Innovative Technology Exchange.

Zacks Equity Research

Alcon (ALC) Gains From Innovation & International Expansion

by Zacks Equity Research

Alcon's (ALC) Surgical business continues to gain from diverse portfolio and incremental innovation.

Zacks Equity Research

Teleflex (TFX) New Survey Highlights BPH Impact Life Quality

by Zacks Equity Research

Teleflex's (TFX) survey results highlight how crucial it is for men to consult a urologist if they have strange or troublesome urine symptoms.

Zacks Equity Research

Charles River (CRL) Announces Partnership With Related Sciences

by Zacks Equity Research

Charles River's (CRL) new collaboration is likely to leverage the AI-powered drug discovery and development platform, Logica.

Zacks Equity Research

Here's Why You Should Retain Insulet (PODD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Insulet (PODD) on the strength of the Omnipod 5 AID system.

Zacks Equity Research

Quest Diagnostics (DGX) to Aid Health Equity With New Pact

by Zacks Equity Research

Quest Diagnostics (DGX) and Americares will provide 10 clinics with no-cost diagnostic services for a year to help patients manage chronic disease.

Zacks Equity Research

Here's Why You Should Retain SmileDirectClub (SDC) Stock for Now

by Zacks Equity Research

Investors are optimistic about SmileDirectClub (SDC) on the latest technology enhancements and upbeat guidance.

Zacks Equity Research

Chemed (CHE) Faces Macroeconomic Woes, Tough Competition

by Zacks Equity Research

Inflationary trend, increased logistics costs and higher employee-related expenses continue to hurt Chemed's (CHE) growth.

Zacks Equity Research

Vicarious Surgical (RBOT) to Broaden User Network With New Deal

by Zacks Equity Research

Vicarious Surgical's (RBOT) partnership with Intermountain Health is likely to help the company gain access to Intermountain Health's extensive network.

Zacks Equity Research

CVS Health's (CVS) New COVID-19 Vaccine Available at Its Stores

by Zacks Equity Research

CVS Health's (CVS) updated mRNA COVID-19 vaccine is now available at all its pharmacy locations.

Zacks Equity Research

Walgreens (WBA) Expands Primary Care Research With New Pact

by Zacks Equity Research

Walgreens (WBA) will reach more communities quickly and provide comprehensive, cost-effective care with the new collaboration.

Zacks Equity Research

SmileDirectClub (SDC) New Alliances Aid, Macro Woes Hurt

by Zacks Equity Research

SmileDirectClub (SDC) is focused on developing transformative innovations to serve the growing needs of the current customer base and expanded segments of higher-income demographics.

Zacks Equity Research

Here's Why You Should Invest in Edward Lifesciences (EW) Now

by Zacks Equity Research

Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of TAVR and a solid balance sheet.

Zacks Equity Research

Syneos Health (SYNH) Declares Strategic Partnership With Oracle

by Zacks Equity Research

Syneos Health (SYNH) announces an expanded collaboration with Oracle to accelerate patient recruitment capabilities.

Zacks Equity Research

Bruker (BRKR) Inks Fraport Framework Contract for ETD Systems

by Zacks Equity Research

Bruker's (BRKR) DE-tector flex system uses a non-radioactive ionization source and is approved by national regulatory bodies and ECAC.